ArticleTranslational vision science & technology2025
Persistent Inflammation After Anti-Tubercular Therapy in Tubercular Serpiginous-Like Choroiditis: A Multivariate and Network-Based Risk Analysis.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to comments on "Intravitreal triamcinolone acetonide therapy in serpiginous-like choroiditis".Indian journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: Antitubercular therapy (ATT) for tubercular serpiginous-like choroiditis (TB-SLC) is well-established, but not infallible. In this study, we investigated the risk factors underlying persistent inflammation after ATT in TB-SLC patients. Methods: We retrospectively reviewed consecutive TB-SLC patients, who completed ≥6 months of ATT. The primary outcome measure was persistent inflammation at the completion of ATT. The risk factors for persistent inflammation were analyzed using multivariate logistic regression. Additionally, a categorical network analysis was performed to explore the relationships among key clinical variables. The anti-inflammatory therapy was quantified as total immunosuppressive load (TIL) by scoring systemic and local corticosteroid treatments. Results: Sixty-five patients, 71% (n = 46) males, with a median age of 33 ± 11.1 years, 45% (n = 29) bilateral, were included. Twelve patients (18.5%; 17 eyes [18.1%]) had ongoing inflammation at the conclusion of ATT. In multivariate regression analysis, the mean TIL at month 1 (adjusted odds ratio, 0.64; 95% confidence interval, 0.43-0.97; P = 0.04) and persistent inflammation at month 3 of ATT (adjusted odds ratio, 13.44; 95% confidence interval, 1.61-111.92; P = 0.02) were risk factors for persistent inflammation after ATT. Network analysis revealed strong mutual associations among low 1-month TIL, persistence at 3 months, paradoxical worsening, and 6-month ATT duration. Conclusions: Initial immunosuppression offers protection, and ongoing inflammation during therapy increases the risk of persistent inflammation after ATT. Paradoxical worsening and shorter ATT duration may affect these risk factors. Translational Relevance: Persistent inflammation after antitubercular therapy for tubercular serpiginous-like choroiditis is mainly determined by nonmicrobial factors, most notably the level of immunosuppression at the start of antitubercular therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.